Search Results

Filter
  • 1-10 of  137 results for ""Lymphoma, Non-Hodgkin""
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

Safety and Effectiveness of Rasburicase in the Control of Hyperuricemia in Pediatric Patients with Non-Hodgkin's Lymphoma and Acute Leukemia: An Open-Label, Single-Arm, Multi-center, Interventional Study.

  • Authors : Wang T; Department of Hematology Center, Beijing Key Laboratory of Pediatric Hematology Oncology, National Key Discipline of Pediatrics (Capital Medical University), Key Laboratory of Major Diseases in Children, Ministry of Education; Hematology Center, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Nanlishi Road No. 56, Xicheng District, Beijing, 100045, People's Republic of China. .

Subjects: Hyperuricemia*/Hyperuricemia*/Hyperuricemia*/complications ; Hyperuricemia*/Hyperuricemia*/Hyperuricemia*/drug therapy ; Lymphoma, Non-Hodgkin*/Lymphoma, Non-Hodgkin*/Lymphoma, Non-Hodgkin*/complications

  • Source: Drugs in R&D [Drugs R D] 2023 Jun; Vol. 23 (2), pp. 129-140. Date of Electronic Publication: 2023 May 10.Publisher: Adis, Springer International Country of Publication: New Zealand NLM ID: 100883647 Publication Model: Print-Electronic Cited Medium: Internet

Record details

×
Report

Preliminary efficacy and safety of Relmacabtagene autoleucel (Carteyva) in adults with relapsed/refractory follicular lymphoma in China: A phase I/II clinical trial.

  • Authors : Ying Z; Department of Lymphoma, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing, China.; Zou D

Subjects: Lymphoma, Follicular*/Lymphoma, Follicular*/Lymphoma, Follicular*/drug therapy ; Lymphoma, Non-Hodgkin*/Lymphoma, Non-Hodgkin*/Lymphoma, Non-Hodgkin*/pathology; Adult

  • Source: American journal of hematology [Am J Hematol] 2022 Dec; Vol. 97 (12), pp. E436-E438. Date of Electronic Publication: 2022 Sep 14.Publisher: Wiley-Blackwell Country of Publication: United States NLM ID: 7610369 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

×
Academic Journal

A phase I pharmacokinetic study of copanlisib in Chinese patients with relapsed indolent non-Hodgkin lymphoma.

  • Authors : Liu W; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital and Institute, No.52 Fucheng Road, Haidian District, Beijing, 100142, China.; Ping L

Subjects: Lymphoma, Non-Hodgkin*/Lymphoma, Non-Hodgkin*/Lymphoma, Non-Hodgkin*/drug therapy ; Phosphatidylinositol 3-Kinases*; China

  • Source: Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2022 Jun; Vol. 89 (6), pp. 825-831. Date of Electronic Publication: 2022 Mar 23.Publisher: Springer Verlag Country of Publication: Germany NLM ID: 7806519 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Burden of All Cancers Along With Attributable Risk Factors in China From 1990 to 2019: Comparison With Japan, European Union, and USA.

  • Authors : Yang X; Clinical Epidemiology Unit, Qilu Hospital of Shandong University, Jinan, China.; Clinical Research Center of Shandong University, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.

Subjects: Lymphoma, Non-Hodgkin* ; Neoplasms*/Neoplasms*/Neoplasms*/epidemiology; China/China/China/epidemiology

  • Source: Frontiers in public health [Front Public Health] 2022 May 26; Vol. 10, pp. 862165. Date of Electronic Publication: 2022 May 26 (Print Publication: 2022).Publisher: Frontiers Editorial Office Country of Publication: Switzerland NLM ID: 101616579 Publication Model: eCollection Cited Medium: Internet

Record details

×
Academic Journal

Burden of lymphoma in China, 1990-2019: an analysis of the global burden of diseases, injuries, and risk factors study 2019.

  • Authors : Liu W; Department of Lymphoma, Key Laboratory of Carcinogenesis and Translational Research Ministry of Education, Peking University Cancer Hospital and Institute, Beijing, China.; Liu J

Subjects: Hodgkin Disease*/Hodgkin Disease*/Hodgkin Disease*/epidemiology ; Lymphoma*/Lymphoma*/Lymphoma*/epidemiology ; Lymphoma, Non-Hodgkin*/Lymphoma, Non-Hodgkin*/Lymphoma, Non-Hodgkin*/epidemiology

  • Source: Aging [Aging (Albany NY)] 2022 Apr 10; Vol. 14 (7), pp. 3175-3190. Date of Electronic Publication: 2022 Apr 10.Publisher: Impact Journals, LLC Country of Publication: United States NLM ID: 101508617 Publication Model: Print-Electronic Cited Medium: Internet

Record details

×
Academic Journal

[Clinical practice guideline for lympoma in China (2021 Edition)].

Subjects: Hodgkin Disease*/Hodgkin Disease*/Hodgkin Disease*/diagnosis ; Hodgkin Disease*/Hodgkin Disease*/Hodgkin Disease*/drug therapy ; Lymphoma*/Lymphoma*/Lymphoma*/diagnosis

  • Source: Zhonghua zhong liu za zhi [Chinese journal of oncology] [Zhonghua Zhong Liu Za Zhi] 2021 Jul 23; Vol. 43 (7), pp. 707-735.Publisher: Chinese Medical Association Country of Publication: China NLM ID: 7910681 Publication Model: Print Cited Medium:

Record details

×
Academic Journal

Translational Applications of Artificial Intelligence and Machine Learning for Diagnostic Pathology in Lymphoid Neoplasms: A Comprehensive and Evolutive Analysis.

  • Authors : Moran-Sanchez J; Division of Hematology and Hemotherapy, Puerta del Mar Hospital, 11009 Cadiz, Spain.; Ph.D Program of Clinical Medicine and Surgery, University of Cadiz, 11009 Cadiz, Spain.

Subjects: Big Data* ; Databases, Factual* ; Diagnosis, Computer-Assisted*

  • Source: Biomolecules [Biomolecules] 2021 May 25; Vol. 11 (6). Date of Electronic Publication: 2021 May 25.Publisher: MDPI Country of Publication: Switzerland NLM ID: 101596414 Publication Model: Electronic Cited Medium: Internet ISSN: 2218-273X

Record details

×
Academic Journal

Bendamustine treatment of Chinese patients with relapsed indolent non-Hodgkin lymphoma: a multicenter, open-label, single-arm, phase 3 study.

  • Authors : Shi YK; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing 100021, China.; Hong XN

Subjects: Lymphoma, Non-Hodgkin*/Lymphoma, Non-Hodgkin*/Lymphoma, Non-Hodgkin*/drug therapy ; Neoplasm Recurrence, Local*/Neoplasm Recurrence, Local*/Neoplasm Recurrence, Local*/drug therapy; Adult

  • Source: Chinese medical journal [Chin Med J (Engl)] 2021 May 06; Vol. 134 (11), pp. 1299-1309. Date of Electronic Publication: 2021 May 06.Publisher: Chinese Medical Association ; produced by Wolters Kluwer Country of Publication: China NLM ID: 7513795 Publication Model:

Record details

×
Academic Journal

Associations between serum carotenoid levels and the risk of non-Hodgkin lymphoma: a case-control study.

  • Authors : Li S; Department of Lymphoma, Cancer Hospital of Xinjiang Medical University, Urumqi830000, Xinjiang, People's Republic of China.; Zhu X

Subjects: Carotenoids/Carotenoids/Carotenoids/*blood ; Lymphoma, Non-Hodgkin/Lymphoma, Non-Hodgkin/Lymphoma, Non-Hodgkin/*etiology; Aged

  • Source: The British journal of nutrition [Br J Nutr] 2020 Dec 28; Vol. 124 (12), pp. 1311-1319. Date of Electronic Publication: 2020 Apr 30.Publisher: Published on behalf of the Nutrition Society by CABI Publishing Country of Publication: England NLM ID: 0372547 Publication Model: Print-Electronic

Record details

×
  • 1-10 of  137 results for ""Lymphoma, Non-Hodgkin""